Lexaria Bioscience has initiated a 2026 animal study to test the compatibility and performance of its DehydraTECH drug delivery platform with two next-generation GLP-1 drugs, amycretin and retatrutide. The study aims to improve drug absorption, reduce side effects like nausea, and explore new intellectual property claims. It will compare pill and capsule formulations and use alternative compounds to enhance drug delivery. Dosing is expected to begin within 30 days, with the study fully funded by Lexaria's existing resources.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
California American Water and Sonoma County Fire District completed projects reducing wildfire risk around water facilities in Sonoma County. The efforts included clearing flammable vegetation near critical infrastructure like water storage tanks and...
